Activin A contributes to the development of hyperoxia-induced lung injury in neonatal mice

Pediatric Research

Volumn 77, Issue 6, 2015, Pages 749-756

  Lim, Rebecca ^a,b   Muljadi, Ruth ^a   Koulaeva, Eugenia ^b   Vosdoganes, Patricia ^b   Chan, Siow Teng ^a   Acharya, Rutu ^a   Gurusinghe, Seshini ^a   Ritvos, Olli ^c   Pasternack, Arja ^c   Wallace, Euan M ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ACTIVIN A RECEPTOR TYPE IIB FC ANTAGONIST; CD45 ANTIGEN; CYTOKINE RECEPTOR ANTAGONIST; FOLLISTATIN; GELATINASE A; GELATINASE B; INTERLEUKIN 6; SMAD3 PROTEIN; UNCLASSIFIED DRUG; ACTIVIN; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR TYPE II-B; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MMP9 PROTEIN, MOUSE; SMAD3 PROTEIN, MOUSE;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FEMALE; HYPEROXIA; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LUNG DYSPLASIA; LUNG INJURY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRONCHOPULMONARY DYSPLASIA; C57BL MOUSE; DRUG EFFECTS; GROWTH DISORDERS; LUNG; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHOSPHORYLATION;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ANIMALS; ANIMALS, NEWBORN; BRONCHOPULMONARY DYSPLASIA; FOLLISTATIN; GROWTH DISORDERS; HYPEROXIA; IMMUNOGLOBULIN FC FRAGMENTS; LUNG; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; PHOSPHORYLATION; RECOMBINANT FUSION PROTEINS; SMAD3 PROTEIN;

EID: 84929858835     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2015.46     Document Type: Article

References (40)

1. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357-68.
2. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. NICHD/NHLBI/ORD Workshop Summary. Am J Resp Crit Care Med 2001;163:1723-9.
3. Kallapur SG, Jobe AH. Contribution of inflammat ion to lung injury and development. Arch Dis Child Fetal Neonatal Ed 2006;91:F132-5.
4. Buckley S, Shi W, Barsky L, Warburton D. TGF-beta signaling promotes survival and repair in rat alveolar epithelia l type 2 cells during recovery after hyperoxic injury. Am J Physiol Lung Cell Mol Physiol 2008;294: L739-48.
5. Sakurai R, Li Y, Torday JS, Rehan VK. Curcumin augments lung maturation, preventing neonat al lung injury by inhibiting TGF-signaling. Am J Physiol Lung Cell Mol Physiol 2011;301:L721-30.
6. Rehan VK, Sakurai R, Corral J, et al. Antenatally administered PPARgamma agonist rosiglitazone pr events hyperoxia-induced neonatal rat lung injury. Am J Physiol Lung Cell Mol Physiol 2010;299:L672-80.
7. Apostolou E, Stavropoulos A, Sountoulidis A, et al. Activin-A overexpression in the murine l ung causes pathology that simulates acute respiratory distress syndrome. Am J Respir Crit Care Med 2012;185:382-91.
8. Aoki F, Kurabayashi M, Hasegawa Y, Kojima I. Attenuation of bleomycininduce d pulmonary fibrosis by follistatin. Am J Respir Crit Care Med 2005;172:713-20.
9. Dasgupta C, Sakurai R, Wang Y, et al. Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{bet a} and Wnt signaling and is protected by rosiglitazone. Am J Physiol Lung Cell Mol Physiol 2009;296:L1031-41.
10. Kunzmann S, Speer CP, Jobe AH, Kramer BW. Antenatal inflammation induced TGF-beta1 but s uppressed CTGF in preterm lungs. Am J Physiol Lung Cell Mol Physiol 2007;292:L223-31.
11. Madurga A, Mi?íková I, Ruiz-Camp J, et al. Systemic hydrogen sulfide administration partially restores normal al veolarization in an experimental animal model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2014;306:L684-97.
12. Buckley S, Warburton D. Dynamics of metalloproteinase-2 and-9, TGFbeta, a nd uPA activities during normoxic vs. hyperoxic alveolarization. Am J Physiol Lung Cell Mol Physiol 2002;283:L747-54.
13. Yee M, Buc zynski BW, Lawrence BP, O'Reilly MA. Neonatal hyperoxia increases sensitivity of adult mice to bleomycin-induced lung fibrosis. Am J Respir Cell Mol Biol 2013;48:258-66.
14. Chen H, Zhuang F, Liu YH, et al. TGF-beta receptor II in epithelia versus mesenchyme plays distinct roles in the developing lung. Eur Respir J 2008;32:285-95.
15. Chen H, Sun J, Buckley S, et al. Abnor mal mouse lung alveolarization caused by Smad3 deficiency is a developmental antecedent of centrilobular emphysema. Am J Physiol Lung Cell Mol Physiol 2005;288:L683-91.
16. Alejandre-Alcázar MA, Kwapiszewska G, Reiss I, et al. Hyperoxia modulates TGF-beta/BMP signaling in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2007;292:L537-49.
17. Glister C, Kemp CF, Knight PG. Bo ne morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: Actions of BMP-4,-6 and-7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin. Reproduction 2004;127:239-54.
18. Sako D, Grinberg AV, Liu J, et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem 2010;285:21037-48.
19. Nüsing RM Barsig J. Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Br J Pharmacol 1999 127 919-26.
20. Brosh N, Sternbe rg D, Honigwachs-Sha'anani J, et al. The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11. Identification as a stroma-derived activin A. J Biol Chem 1995;270:29594-600.
21. Wang SY Tai GX Zhang PY Mu DP Zhang XJ Liu ZH.Inhibitory effect of activin A on activation of lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Cytokine 2008 42 85-91.
22. Segerer S.E. Müller N Brandt Jv et al. The glycoprotein-hormones activin A and inhibin A interfere with dendritic cell maturation. Reprod Biol Endocrinol. 2008. 6. 17.
23. Huber S, Stahl FR, Schrader J, et al. Activin a promotes the TGF-beta-induced conversion of CD4+CD25-T cells into Foxp3+ induced regulatory T cells. J Immunol 2009;182:4633-40.
24. Semitekolou M, Ali ssafi T, Aggelakopoulou M, et al. Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease. J Exp Med 2009;206:1769-85.
25. Ogawa K, Funaba M, Chen Y, Tsujimoto M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol 2006;177:6787-94.
26. Ohga E, Matsuse T, Tera moto S, Ouchi Y. Activin receptors are expressed on human lung fibroblast and activin A facilitates fibroblast-mediated collagen gel contraction. Life Sci 2000;66:1603-13.
27. Sierra-Filardi E, Puig-Kröger A, Blanco FJ, et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 2011;117:5092-101.
28. Jones CV, Williams TM, Walker KA, et al. M2 macrophage polarisation is associated with alveolar formation during postnatal lung development. Respir Res 2013;14:41.
29. Pardo A, Selman M, Ridge K, Barrios R, Sznajder JI. Increased expression of gelatinases and collagenase in rat lungs exposed to 100% oxygen. Am J Respir Crit Care Med 1996;154(4 Pt 1):1067-75.
30. Curley AE, Sweet DG, Thornton CM, et al. Chorioamnionitis and increased neonatal lung lavage fluid matrix metalloproteinase-9 levels: Implications for antenatal origins of chronic lung disease. A m J Obstet Gynecol 2003;188:871-5.
31. Sweet DG, Curley AE, Chesshyre E, et al. The role of matrix metalloproteinases-9 and-2 in development of neonatal chronic lung disease. Acta Paediatr 20 04;93:791-6.
32. Chetty A, Cao GJ, Severgnini M, Simon A, Warburton R, Nielsen HC. Role of matrix metalloprotease-9 in hyperoxic injury in developing lung. Am J Physiol Lung Cell Mol Physiol 2008;295:L584-92.
33. Hardy CL, Nguyen HA, Mohamud R, et al. The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax 2013;68:9-18.
34. Yee M, Buczynski BW, Lawrence BP, O'Reilly MA. Neonatal hyperoxia increases sensitivity of adult mice to bleomycin-induced lung fibrosis. Am J Respir Cell Mol Biol 2013;48:258-66.
35. Rock JR, Hogan BL. Epithelial progenitor cells in lung development, maintenance, repair, and disease. Annu Rev Cell Dev Biol 2011;27:493-512.
36. Thébaud B. Angiogenesis in lung development, injury and repa ir: Implications for chronic lung disease of prematurity. Neonatology 2007;91:291-7.
37. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculat ure and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164(10 Pt 1):1971-80.
38. Thébaud B, Ladha F, Michelakis ED, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: Evidence that angiogenesis participates in alveolarization. Circulation 2005;112: 2477-86.
39. Vosdoganes P, Lim R, Koulaeva E, et al. Human amnion epithelial cells modulate hyperoxia-induced neonatal lung injury in mice. Cytotherapy 2013;15:1021-9.
40. Hoogaars WM, Mouisel E, Pasternack A, et al. Combined effect of AAVU7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice. Hum Gene Ther 2012;23:126 9-79.